TTM
81.7%
YoY change
+0.77pp
Trough year (2021)
66.8%
Peak year (2009)
82.4%
Latest annual
81.9%
Gross Margin history chart for AstraZeneca (AZN) from 1998 to 2025
Latest: 81.9%
Gross Margin change chart for AstraZeneca (AZN) from 1998 to 2025
Latest: +0.77pp
Gross Margin history table for AstraZeneca (AZN) from 1998 to 2025
| 2025 | 81.9% | +0.77pp | ||
| 2024 | 81.1% | -0.83pp | ||
| 2023 | 82.0% | +9.89pp | ||
| 2022 | 72.1% | +5.30pp | ||
| 2021 | 66.8% | -13.33pp | ||
| 2020 | 80.1% | +0.27pp | ||
| 2019 | 79.8% | +2.16pp | ||
| 2018 | 77.7% | -3.12pp | ||
| 2017 | 80.8% | -1.28pp | ||
| 2016 | 82.1% | +0.87pp | ||
| 2015 | 81.2% | +3.20pp | ||
| 2014 | 78.0% | -1.62pp | ||
| 2013 | 79.6% | -1.11pp | ||
| 2012 | 80.7% | -1.34pp | ||
| 2011 | 82.1% | +1.26pp | ||
| 2010 | 80.8% | -1.60pp | ||
| 2009 | 82.4% | +3.27pp | ||
| 2008 | 79.1% | +0.84pp | ||
| 2007 | 78.3% | -0.72pp | ||
| 2006 | 79.0% | +1.37pp | ||
| 2005 | 77.6% | +1.87pp | ||
| 2004 | 75.8% | -0.56pp | ||
| 2003 | 76.3% | +1.66pp | ||
| 2002 | 74.7% | +1.70pp | ||
| 2001 | 73.0% | — | ||
| 1999 | 78.5% | -3.52pp | ||
| 1998 | 82.1% | — |
- 202581.9%+0.77pp
- 202481.1%-0.83pp
- 202382.0%+9.89pp
- 202272.1%+5.30pp
- 202166.8%-13.33pp
- 202080.1%+0.27pp
- 201979.8%+2.16pp
- 201877.7%-3.12pp
- 201780.8%-1.28pp
- 201682.1%+0.87pp
- 201581.2%+3.20pp
- 201478.0%-1.62pp
- 201379.6%-1.11pp
- 201280.7%-1.34pp
- 201182.1%+1.26pp
- 201080.8%-1.60pp
- 200982.4%+3.27pp
- 200879.1%+0.84pp
- 200778.3%-0.72pp
- 200679.0%+1.37pp
- 200577.6%+1.87pp
- 200475.8%-0.56pp
- 200376.3%+1.66pp
- 200274.7%+1.70pp
- 200173.0%—
- 199978.5%-3.52pp
- 199882.1%—
Gross Margin values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Margin at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's latest reported gross margin is 81.7%. Gross margin is gross profit divided by revenue, expressed as a percentage. It shows how much of each sales dollar survives the direct cost of goods sold — before operating expenses, interest, and taxes. A higher gross margin generally signals pricing power and production efficiency. Margins are most meaningful compared against sector peers and a company's own history.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, AstraZeneca (AZN) reported gross margin of 81.90% – expanded 0.8 percentage points year-over-year.
2009 marks the peak gross margin at 82.40%, with the historical low of 66.76% recorded in 2021.
AstraZeneca Gross Margin by Year
AstraZeneca Gross Margin 2025: 81.9%
In 2025, AstraZeneca reported gross margin of 81.90%, expanded 0.8 percentage points from 2024.
AstraZeneca Gross Margin 2024: 81.1%
AstraZeneca gross margin in 2024 was 81.12%, contracted 0.8 percentage points from 2023.
AstraZeneca Gross Margin 2023: 82.0%
2023's gross margin for AstraZeneca came in at 81.95%, expanded 9.9 percentage points from 2022.
AstraZeneca Gross Margin 2022: 72.1%
AstraZeneca posted gross margin of 72.06% in 2022, expanded 5.3 percentage points from 2021.
AstraZeneca Gross Margin 2021: 66.8%
AstraZeneca gross margin in 2021 was 66.76%.
See more financial history for AstraZeneca (AZN).
Sector peers by Gross Margin
Healthcare peers of AstraZeneca (AZN), ranked by their latest gross margin
| 83.5% | |
| 81.8% | |
| 75.9% | |
| 71.5% | |
| 70.7% | |
| 70.0% | |
| 39.4% | |
| 18.8% |
- 83.5%
- 81.8%
- 75.9%
- 71.5%
- 70.7%
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation